NewsBenzingaHC Wainwright & Co. réitère son opinion d’achat sur Scribe Therapeutics et maintient son objectif de cours à 60 $ HC Wainwright & Co. réitère son opinion d’achat sur Scribe Therapeutics et maintient son objectif de cours à 60 $ Benzinga 2026.11.19 11:28 (GMT+0) Open on Benzinga Other news HC Wainwright & Co. Reiterates Buy on Tempus AI, Maintains $85 Price Target HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $20 Kash Patel Skips House Hearing After Attending Trump’s Mar-a-Lago Gala Offering $50,000 Access to Top Officials, Draws Bipartisan Criticism: Report HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
Kash Patel Skips House Hearing After Attending Trump’s Mar-a-Lago Gala Offering $50,000 Access to Top Officials, Draws Bipartisan Criticism: Report